Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 16/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 16/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22400072 | 1.00 | CYP3A4 (0.79) | CYP3A4CYP2D6 | |
| SCHEMBL24722423 | 0.96 | CYP3A4 (0.87) | CYP3A4CYP2D6 | |
| SCHEMBL24722278 | 0.93 | CYP3A4 (0.81) | CYP3A4CYP2D6 | |
| SCHEMBL23425491 | 0.91 | CYP2D6 (0.93) | CYP3A4CYP2D6 | |
| SCHEMBL23425492 | 0.91 | CYP2D6 (0.93) | CYP3A4CYP2D6 | |
| SCHEMBL23425490 | 0.91 | CYP2D6 (0.93) | CYP3A4CYP2D6 | |
| SCHEMBL20644352 | 0.90 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| SCHEMBL20644335 | 0.90 | CYP3A4 (0.77) | CYP3A4CYP2D6 | |
| SCHEMBL10049618 | 0.90 | CYP2D6 (0.82) | CYP3A4CYP2D6 | |
| SCHEMBL17562039 | 0.90 | CYP2D6 (0.82) | CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389038-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX, INC. (CN) | 2022-12-08 | — | — | US | disclosed |
| US-20200369696-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | SHENZHEN TARGETRX, INC. (CN) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369696-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | TYMP, HPRT1, POLRMT | CYP3A4 381/4885CYP2D6 293/4885 |
| US-20220389038-A1 | ANTIVIRAL NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR | TYMP, HPRT1, POLRMT | CYP3A4 381/4885CYP2D6 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.